Deregulated expression of BCL6 is a pathogenic event in many lymphomas. BCL6 blocks cellular differentiation by repressing transcription of its target genes, and this may promote tumorigenesis. Conversely, the transcription factor signal transducers and activators of transcription (STAT)5 promotes differentiation in many systems. STAT5 upregulates a number of genes repressed by BCL6, raising the possibility that STAT5 and BCL6 have opposing roles in transcriptional regulation. Therefore, we sought to determine the effects of STAT5 activation on BCL6 expression and function. We found that activation of STAT5 downregulates BCL6 expression in B-lymphoma cells and other hematopoietic cell lines. We identified two potential STAT-binding regions in the first exon and first intron of BCL6 that fell within regions of high interspecies homology, suggesting conservation of regulatory function. STAT5 can bind inducibly and regulate transcription at one of these regions, identifying BCL6 as a STAT5 target gene. Additionally, STAT5-mediated downregulation of BCL6 results in loss of BCL6 repression of its target genes, confirming that STAT5 is a negative regulator of BCL6 function. The STAT5 responsive region of the BCL6 gene is mutated frequently in B-cell lymphomas, suggesting that loss of the repressive effects of STAT5 on BCL6 might contribute to the pathogenesis of these cancers.
Introduction
Dysregulation of the transcriptional repressor BCL6 occurs frequently in lymphomas (Baron et al., 1993; Kerckaert et al., 1993; Ye et al., 1993) . BCL6 is located at 3q27, a site of many chromosomal breaks, fusions and point mutations that are often found in B-cell lymphomas (Migliazza et al., 1995; Chaganti et al., 1998; Ichinohasama et al., 1998; Lossos et al., 2003) . These mutations result in overexpression of BCL6, which is likely owing to disruption of critical negative regulatory sequences Chen et al., 1998; Pasqualucci et al., 2003) . Overexpression of BCL6 has been shown to promote lymphoma in mice (Baron et al., 2004; Cattoretti et al., 2005) , suggesting that deregulation of BCL6 expression may be a critical step in lymphomagenesis.
Although BCL6 is highly expressed in germinal center B-cells, it is also expressed in diverse tissues including skeletal muscle, breast, prostate and olfactory sensory neurons (Bajalica-Lagercrantz et al., 1997; Logarajah et al., 2003; Otaki et al., 2005) . BCL6 is not expressed in terminally differentiated plasma cells; however, forced expression of BCL6 in plasma cells causes a loss of terminal differentiation markers and reversion to a less differentiated state. By contrast, downregulation of BCL6 by RNA interference causes mature B-cells to express plasma cell markers (Fujita et al., 2004) . These data suggest that BCL6 is a master regulator of B-cell differentiation. Additionally, overexpression of BCL6 in mammary cells blocks terminal differentiation (Logarajah et al., 2003) , suggesting that BCL6 blocks differentiation in non-hematopoietic cells as well. BCL6 expression results in repression of genes normally expressed in terminally differentiated cells, including CD69, CD80, XBP-1, MIP1a and b-casein (Shaffer et al., 2000; Logarajah et al., 2003; Niu et al., 2003) . Interestingly, b-casein and MIP1a are also regulated by signal transducers and activators of transcription (STAT) transcription factors (Happ and Groner, 1993; Nelson et al., 2004) .
STATs are a family of seven proteins that regulate a variety of cellular functions (Darnell, 1997) . Under basal conditions, STATs are found in the cytoplasm. Upon activation by tyrosine phosphorylation, STATs enter the nucleus and modulate expression of genes involved in many functions, including survival, differentiation and apoptosis (Horvath, 2000) . Aberrant activation of STATs, especially STAT5, is found in numerous cancers, including hematopoietic cancers (Frank, 1999; Bowman et al., 2000; Lin et al., 2000) . Chronic myelogenous leukemia (CML) is a prototypical tumor displaying constitutive STAT5 activation. CML is characterized by the Bcr-Abl fusion oncoprotein, which leads to constitutively active STAT5, promoting growth and preventing apoptosis (Shuai et al., 1996; de Groot et al., 1999; Sillaber et al., 2000) . STAT5 refers to two highly homologous but separate genes, STAT5a and STAT5b, which have both overlapping and distinct functions (Liu et al., 1995; Teglund et al., 1998) . Constitutively active STAT5b, but not STAT5a, contributes to the tumorigenecity of squamous cell carcinoma of the head and neck (Leong et al., 2002; Xi et al., 2003) , suggesting that STAT5b may be the oncogenic form of STAT5. Intriguingly, STAT5b is overexpressed in diffuse large B-cell lymphoma (DLBCL) (Shipp et al., 2002) , and STAT5 is constitutively active in some DLBCL cell lines (Melzner et al., 2005) , suggesting that both STAT5 and BCL6 may be important determinants in DLBCL pathogenesis.
STAT5 has been shown to promote both survival and differentiation in a number of cells, including hematopoietic and mammary cells (Nosaka et al., 1999; Buitenhuis et al., 2003; Cui et al., 2004) . Recently, the critical role of STAT5a in promoting survival and differentiation of hematopoietic stem cells has been demonstrated (Schuringa et al., 2004) . Introduction of constitutively active STAT5a in human cord blood cells resulted in the upregulation of a variety of STAT5 target genes and markers of terminal differentiation, with a coincident downregulation of BCL6 expression (Schuringa et al., 2004) , suggesting the possibility that STAT5 may regulate BCL6 expression either directly or indirectly during differentiation.
Although STAT5 activates expression of a number of genes, including cytokine-induced Src homology 2-containing protein (CIS), bcl-xl, and the terminal differentiation markers b-casein and MIP1a (Happ and Groner, 1993; Matsumoto et al., 1997; Socolovsky et al., 1999; Nelson et al., 2004) , STAT5 can also act as a transcriptional repressor (Luo and Yu-Lee, 1997; Nelson et al., 2004) . Furthermore, BCL6 has been shown to repress transcription of a number of genes independently identified as STAT5 targets (Shaffer et al., 2000; Tang et al., 2002; Logarajah et al., 2003; Fernandez de Mattos et al., 2004) , suggesting that STAT5 and BCL6 may have reciprocal roles on gene expression and function.
As STAT5 and BCL6 have opposite roles on differentiation and gene regulation, we wanted to determine the functional relationship between STAT5 and BCL6. We show that STAT5 represses BCL6 expression in B-lymphoma cells and other hematopoietic cells. By identifying non-protein coding sequences of the BCL6 gene that display high inter-species homology, two potential STAT-binding regions were identified, one of which demonstrated both STAT5-mediated transcriptional responsiveness and direct in vivo binding of STAT5. We identified BCL6 as a direct transcriptional target of STAT5 and demonstrated that STAT5 represses BCL6 expression by binding to the first untranslated exon of BCL6. This STAT5 regulatory site is frequently mutated in lymphomas, suggesting that loss of repression of BCL6 by STAT5 may be a critical step in tumor pathogenesis.
Results
BCL6 expression correlates inversely with STAT5 activation As BCL6 and STAT5 have opposing roles on survival and differentiation and have opposite functions on specific target genes, we first determined the relationship between STAT5 activation and BCL6 expression. Given its known role in normal and neoplastic B-cell function, we analysed BCL6 expression in the mouse B-lymphoma line BCL1. Interleukin (IL)-2 stimulation of BCL1 cells resulted in prominent STAT5 phosphorylation (Figure 1a) . Stimulation of BCL1 cells with IL-2 resulted in the upregulation of the well-characterized STAT5 target gene CIS and prominent downregulation of BCL6 expression (Figure 1b ). This suggested that STAT5 activation caused repression of BCL6 expression. To determine whether this relationship occurred in other hematopoietic cells, we examined NKL cells, an IL-2-dependent natural killer cell line (Robertson et al., 1996) , which upon stimulation with IL-2 showed prominent activation of STAT5 (Figure 1c) . Stimulation of NKL cells with IL-2 led to a marked upregulation of the STAT5 target gene CIS, with a concurrent decrease in BCL6 mRNA and protein expression (Figure 1d and e). This demonstrates that IL-2-induced STAT5 activation results in downregulation of BCL6 in NK cells as well as in B-cells. To determine whether the association of STAT5 activation with BCL6 downregulation was unique to IL-2 stimulation, 32D cells, an IL-3-dependent myeloid cell line, were utilized. Stimulation of 32D cells with IL-3 resulted in phosphorylation of STAT5 (Ilaria et al., 1999 , and data not shown). This was associated with prominent upregulation of the STAT5 target gene CIS and marked downregulation of BCL6 mRNA expression (Figure 1f ). These findings demonstrate that multiple stimuli that activate STAT5 cause downregulation of BCL6 expression.
Cytokines can activate signaling pathways other than STATs, such as the phosphatidylinositol 3 0 -kinase and mitogen-activated protein kinase (MAPK) pathways. To exclude the possibility that these pathways were causing the repression of BCL6, specific inhibitors were utilized. Inhibition of PI3 kinase with LY294002, or MAP-kinase kinase with UO126 did not affect IL-3-induced downregulation of BCL6 mRNA (Supplementary Figure 1a and b), demonstrating that cytokineinduced downregulation of BCL6 is not mediated by either of these pathways. As cytokines may activate other STAT family members in addition to STAT5, we employed a system known to contain activated STAT5, but not activated STAT1 or STAT3. K562 cells express Bcr-Abl (Lozzio and Lozzio, 1975) and display constitutively active STAT5. STI-571 (Gleevec, imatinib mesylate) directly inhibits Bcr-Abl, leading to inhibition of STAT5 activation (Druker et al., 1996) . Treatment of K562 cells with STI-571 resulted in inhibition of both STAT5a and STAT5b phosphorylation ( Figure 1g ). Given this, the effect of STI-571 treatment of K562 cells on BCL6 expression was tested. 2 h after treatment with STI-571, the mRNA expression of the STAT5 target gene CIS was significantly inhibited, whereas BCL6 mRNA expression was upregulated about 2.5-fold ( Figure 1h ). Thus, the inhibition of STAT5 reverses the transcriptional regulation of both CIS and BCL6. Together, these results indicate that BCL6 is expressed and regulated in a variety of hematopoietic lineages, and that modulation of STAT5 activation inversely correlates with changes in BCL6 expression.
To demonstrate that STAT5 is directly causing the downregulation of BCL6, a well-characterized inducible system of constitutively activated STAT5 (STAT5a1*6) was employed (Onishi et al., 1998; Gesbert and Griffin, 2000; Rascle et al., 2003) . Upon treatment of Ba/f3-tet-1*6 cells with doxycycline (dox), STAT5a1*6 is expressed . Treatment with dox resulted in the upregulation of the STAT5 target gene CIS with a concurrent downregulation of BCL6 expression ( Figure 1i ). This demonstrates that BCL6 is a direct target of STAT5 and identifies BCL6 as one of only a few genes known to be repressed by STAT5.
STAT5 blocks BCL6-mediated transcriptional repression
Having demonstrated that STAT5 downregulates BCL6 expression, we next determined if this led to changes in BCL6 transcriptional function. Therefore, we analysed the expression of a number of BCL6 target genes to determine if modulation of BCL6 mRNA expression by STAT5 resulted in changes in BCL6 repression of BCL6 target genes. NKL cells were starved of IL-2 and then stimulated with IL-2 for 24 h. Activation of STAT5 by IL-2 led to a loss of BCL6 expression (Figure 2a ). 
STAT5 negatively regulates BCL6
SR Walker et al Furthermore, the repression of the BCL6 target genes CD69, CD80 and XBP-1 was reversed when BCL6 was no longer expressed ( Figure 2a) . To examine the effects of relieving STAT5 activation on BCL6 expression and its target genes, K562 cells were treated with STI-571. BCL6 expression was upregulated with STI-571, resulting in repression of the BCL6 target genes CD69, CD80 and XBP-1 (Figure 2b ). Therefore, activation of STAT5 leads to downregulation of BCL6 expression, culminating in loss of BCL6 regulation of its target genes, whereas inhibition of STAT5 allows BCL6 transcriptional repression to occur. This demonstrates that the activation status of STAT5 has direct effects on BCL6 function, as measured by the expression of BCL6 target genes.
STAT5 does not affect BCL6 mRNA stability
Although it is likely that STAT5 modulates BCL6 mRNA through inhibition of transcription, it is not known how STAT5 represses gene expression, and therefore it is possible that STAT5 represses BCL6 by decreasing mRNA stability. To test this hypothesis, NKL cells were treated with the transcriptional inhibitor actinomycin D, and the half-life of BCL6 mRNA was determined. In the absence of activated STAT5, the half-life of BCL6 mRNA is approximately 65 min. IL-2 stimulation did not have a significant effect on the decay rate of BCL6 mRNA (data not shown), demonstrating that STAT5 does not repress BCL6 expression by affecting the stability of BCL6 mRNA.
Identification of potential STAT-binding sites
To determine if STAT5 downregulates BCL6 by binding to the BCL6 promoter, we sought to locate a functional STAT5-binding site within the BCL6 gene. Human BCL6 has two mRNA variants that differ in their first untranslated exon, but result in the same protein ( Figure 3a) . Given that regulatory regions are often conserved among species (Hardison et al., 1997; Brudno et al., 2004) , we searched for regions of homology in non-protein coding areas of the BCL6 gene for the STAT consensus site, TTC(N 3 )GAA. We focused on the first intron, as the majority of STAT5-binding sites occur within introns (Nelson et al., 2004) . We also noted that the homology for the first part of exon 1 was very low, whereas the homology was nearly 100% for the second part of exon 1 extending 300 base pairs into the intron. This region of homology is unlike the other exon/intron boundaries in the BCL6 gene (data not shown), suggesting that this region might contain important conserved regulatory elements. Additionally, both the first exon and intron are often mutated in cancer (Ye et al., 1993; Migliazza et al., 1995) , which further suggested that these regions might contain potential regulatory regions. Therefore, we analysed STAT5 negatively regulates BCL6 SR Walker et al possible STAT-binding sites in the first exon and first intron using the program Match, as well as manually searching for STAT consensus sites. We identified 10 potential STAT-binding sites, with two regions containing clusters of three or more of these sites. This is of potential importance as STAT5 may bind cooperatively to neighboring sites (Moriggl et al., 2005) . One of these sequences, which has three STAT consensus sites and maps to the first intron ( þ 8029 to þ 8130) (Figure 3b) , was designated region A. The other sequence, which contains four STAT consensus sites and maps to the first untranslated exon near the exon/intron boundary ( þ 441 to þ 544), was designated region B (Figure 3c ). Both region A and region B contain sequences of high homology between human, mouse and rat ( Figure 3d ) and all of the STAT consensus sites within these regions are 100% conserved among these species. This level of conservation suggests that one or both of these regions might be important for transcriptional regulation. Therefore, we sought to determine if these sequences mediate repression by STAT5.
Region B confers STAT5 responsiveness
To determine if STAT5 could regulate transcription through region A or B, we inserted each sequence upstream of a luciferase reporter gene (A-Luc and BLuc, respectively). 293 cells were transfected with either construct and a constitutively active STAT5 mutant, STAT5a1*6. Luciferase expression was induced about 40-fold from B-Luc but only threefold from A-Luc (Figure 4a ). This suggested that region B, but not A, was STAT5 responsive. As activation of STAT5 is associated with decreased BCL6 expression, it might be expected that STAT5 would mediate repression of a luciferase gene downstream of region B. However, the finding that B-Luc is activated by STAT5 suggests that region B, which is clearly STAT5 responsive, needs to be in the proper genomic or chromatin context to mediate gene repression. Similar findings have been seen with other regulatory regions mediating repression, such as the interferon response factor-1 promoter (Luo and YuLee, 1997) . Therefore, we isolated a fragment of BCL6 that included the TATA box through region B and inserted this upstream of a luciferase gene, which put region B in the proper genomic orientation relative to the start of transcription. To directly test if STAT5 mediates repression of this construct (TBR-Luc), we transfected 293 cells with a constitutively active form of STAT5 (STAT5a1*6). Although STAT5a1*6 upregulated luciferase expression 40-fold from B-Luc (Figure 4a ), STAT5a1*6 downregulated luciferase by about 35% from TBR-Luc (Figure 4b ). This demonstrates that region B is STAT5 responsive, and that transcriptional repression by STAT5 requires that the region be in its appropriate genomic context.
STAT5 binds to the a STAT-binding site of region B of BCL6 in vitro
Having demonstrated that region B is STAT5 responsive, we wanted to identify which potential STATbinding site within region B was bound by STAT5. Region B contains four STAT consensus sites, which we designated a, b, g and d (Figure 3c ). Nuclear extracts of NKL cells stimulated with IL-2 were incubated with 32 P-labeled probes for each site and analysed by electrophoretic mobility shift assay (EMSA). Although weak complexes were seen with the b and d sites, prominent inducible protein-DNA complexes were found only with the a site ( Figure 5 ). Furthermore, antibodies specific to STAT5 but not STAT3 supershifted the complex, conclusively demonstrating that the a site of region B ( þ 459 to þ 467) is a binding site specific to STAT5.
STAT5 binds to region B of BCL6 in vivo
Having demonstrated that STAT5 binds to the a site in region B of the BCL6 gene in vitro, we wanted to directly assess if STAT5 binds to region B of BCL6 in vivo. Therefore, we performed chromatin immunoprecipitation (ChIP) assays on NKL cells stimulated by IL-2 and analysed STAT5 binding to various regions of BCL6 Figure 4 Region B of the BCL6 gene is STAT5 responsive. 293 cells were transfected with A-Luc or B-Luc (a) or TBR-Luc (b), and STAT5a1*6 or vector control, and analysed for luciferase activity after 24 h. (Figure 6a ). IL-2 stimulation led to the inducible association of STAT5 with region B (Figure 6b and c) . This association was specific to STAT5, as nonspecific immunoglobulin (Ig)G did not immunoprecipitate region B. Consistent with the reporter assay data (Figure 4a ), STAT5 did not bind to region A in NKL cells stimulated with IL-2 (Figure 6c ). In addition, STAT5 did not bind to a control region located 5 0 of the transcription start site of BCL6 (Figure 6c ). These results demonstrate that BCL6 is a direct STAT5 target, and that the STAT5-binding site is region B. To exclude the possibility that other STATs might be contributing to the regulation of BCL6, ChIP was performed on NKL cells using antibodies specific to the related proteins STAT1 and STAT3. Neither STAT1 nor STAT3 inducibly bound to region B upon IL-2 stimulation (Supplementary Figure 2) , further demonstrating the specific and inducible binding of STAT5 to region B of BCL6. To determine whether STAT5 similarly bound to this site in a B-lymphoma cell line, BCL1 cells were stimulated with IL-2 and analysed by ChIP. STAT5, but not STAT1 nor STAT3, bound inducibly upon IL-2 stimulation to region B (Figure 6d ). This demonstrates that STAT5 binds in vivo to region B in a variety of hematopoietic cell types, and that BCL6 is a direct transcriptional target of STAT5.
Discussion
We have identified BCL6 as a STAT5 target gene, and have demonstrated that upon activation, STAT5 binds to the first exon of BCL6, leading to downregulation of BCL6 expression. In addition, downregulation of BCL6 expression results in loss of BCL6 repression of its target genes. We analysed non-coding regions of the BCL6 gene and identified two potential STAT-binding regions within the first untranslated exon and first intron of Figure 5 STAT5 binds to the a STAT site ( þ 459 to þ 467) of region B in vitro. EMSA was performed with nuclear extracts of NKL cells that were untreated or stimulated with IL-2, using probes specific for each of the four potential STAT-binding sites of region B (Figure 3c ). Antibodies to STAT5 or STAT3 were used to determine constituents of the complex. STAT5 negatively regulates BCL6 SR Walker et al BCL6, which display high inter-species homology. This suggested that these were important regulatory regions, and we determined that one of these sites was in fact bound by STAT5 in vivo. These results validate the approach of identifying functional transcription factor binding sites by identifying regions of high inter-species homology in non-protein coding regions of genes.
When region B of BCL6 was introduced upstream of a reporter gene, it conferred STAT5 responsiveness. However, when STAT5 is activated, B-Luc activity is upregulated (Figure 4a) , whereas BCL6 mRNA expression is downregulated (Figure 1) . Interestingly, when inserted in the correct genomic context, with the start of transcription upstream of region B (TBR-Luc), STAT5 mediated repression of the reporter gene (Figure 4b ). This demonstrates that the positional orientation of region B is critical for STAT5-mediated repression, and that out of context, regions that confer repression may also activate transcription.
Repression of target genes by STAT5 has only recently been identified (Luo and Yu-Lee, 1997; Nelson et al., 2004) , and the mechanism by which STAT5 represses genes remains largely unknown. An interaction between STAT5 and the nuclear co-repressor SMRT has been identified, suggesting the possibility that STAT5 recruits SMRT to repress expression of target genes (Nakajima et al., 2001 ). Interestingly, we have shown that activation of STAT5 by one stimulus leads to upregulation of genes such as CIS, as well as downregulation of other genes such as BCL6 in the same cell type at the same time (Figure 1 ). This demonstrates that STAT5 acts as a bifunctional transcription factor and suggests that there may be distinct partners that cooperate with STAT5 to upregulate or downregulate a particular target gene.
It has recently been demonstrated that BCL6 expression is upregulated by interferon gamma-induced activation of STAT1 (Zhou and Ono, 2005) . Interestingly, it was shown that STAT1 bound to the sequence we designated region B, specifically the a STAT site. This suggested that STAT1 may also be regulating BCL6. Additionally, it has been shown that expression of activated STAT3 in fibroblasts leads to upregulation of BCL6 expression (Alvarez et al., 2005) , raising the possibility that STAT3 may also regulate BCL6 expression. In addition to activating STAT5, IL-2 also can activate STAT1 and STAT3 (Frank et al., 1995) . However, ChIP assays in both BCL1 and NKL cells demonstrated clearly that neither STAT1 nor STAT3 bound inducibly to region B following stimulation with IL-2 (Figure 6d and Supplementary Figure 2) . Thus, other cell type or cytokine-dependent factors may allow STAT1-or STAT3-dependent regulation of BCL6 in other systems.
Recently, it has been demonstrated that STAT5 upregulates BCL6 in a subset of germinal center cells (Scheeren et al., 2005) . Using reporter assays, it was demonstrated that the STAT5-binding site was located at À526 to À534 according to the þ 1 nucleotide defined by Ohashi et al. (1995) . Analysis of this site demonstrated that it is not highly conserved among human, rat and mouse (data not shown). Additionally, we utilized this site in our ChIP experiments as the control region (Figure 6a) , and in NKL cells stimulated with IL-2, STAT5 does not bind to that site (Figure 6c ). It is possible that the site identified by Scheeren et al. (2005) is a STAT5-binding site specific to germinal center cells in which STAT5 upregulates BCL6 expression. Therefore, STAT5 may be upregulating BCL6 in some cell types and downregulating BCL6 expression in other cell types.
Under normal physiologic conditions, BCL6 has been shown to repress differentiation of B-cells as well as mammary cells, whereas STAT5 has been shown to promote differentiation of hematopoietic and mammary cells. IL-2 promotes differentiation of BCL1 B-lymphoma cells (Messika et al., 1998) , and we have demonstrated that IL-2 activates STAT5 and causes downregulation of BCL6 expression in these cells. This suggests that STAT5 downregulates BCL6 to promote differentiation via a two-step method such that STAT5 not only upregulates its target genes, but also promotes differentiation by downregulating BCL6, allowing expression of genes normally repressed by BCL6. Interestingly, recent work has demonstrated that hematopoietic stem cells expressing an activated form of STAT5 can differentiate into erythroid cells, and these cells show downregulation of BCL6 expression (Schuringa et al., 2004) . This suggests that downregulation of BCL6 by STAT5 is necessary for hematopoietic stem cells to differentiate, and raises the possibility that forced expression of BCL6 could directly block hematopoietic stem cell differentiation. It is also possible that BCL6 could inhibit STAT5 expression or activation, which then blocks differentiation. Therefore, both STAT5 and BCL6 may be master regulators of differentiation of a variety of systems.
BCL6 is overexpressed in a number of lymphomas and has been shown to promote lymphomas in mice. BCL6 is found in a chromosomal region often involved in translocations, deletions and insertions. Additionally, a number of point mutations have been identified within the first exon and first intron of the gene. These mutations may dramatically change the regulation of BCL6 expression, resulting in overexpression of BCL6. One possible mechanism may be through loss of autoregulation by BCL6 itself (Kikuchi et al., 2000; Pasqualucci et al., 2003) . Another mechanism may be through loss of binding of other negative regulatory elements. In a number of hematopoietic lineages, we have demonstrated that STAT5 negatively regulates BCL6 expression by binding to region B. Interestingly, region B falls within a 'hot spot' of mutations, raising the possibility that these mutations could block STAT5 binding, and therefore, block repression, resulting in overexpression of BCL6. STAT5 is activated aberrantly in a variety of tumors, including DLBCL (Melzner et al., 2005) , and may contribute to tumorigenesis by increasing expression of pro-survival genes. However, activation of STAT5 would be expected to repress BCL6 expression. Thus, mutations in the STAT5-binding site would allow tumors to have both activated STAT5 as well as high BCL6 expression.
This study demonstrates that STAT5 directly represses BCL6 expression. This results in a loss of repression of BCL6 target genes, thereby allowing cells to differentiate. Mutations of the STAT5 regulatory region may deregulate BCL6 expression, promoting lymphomas and possibly other tumors.
Materials and methods
Cell lines NKL cells (Robertson et al., 1996) were maintained in Rosewell Park Institute media (RPMI) 1640 containing 10% fetal calf serum (FCS) and recombinant human IL-2 (25 U/ml) (R&D Systems, Minneapolis, MN, USA). K562 cells and 32D cells (kindly provided by James Griffin, Dana-Farber Cancer Institute, Boston, MA, USA) and Ba/f3-tet-1*6 cells (kindly provided by Martin Sattler, Dana-Farber Cancer Institute, Boston, MA, USA) were maintained in RPMI 1640 containing 10% FCS. 32D cells and Ba/f3-tet-1*6 cells were supplemented with 1 ng/ml recombinant mouse IL-3 (R&D Systems). BCL1-5B1b cells (ATCC, Manassas, VA, USA) were maintained in RPMI 1640 containing 15% FCS. 293 cells, were maintained in Dulbecco's modified Eagle's medium supplemented with 10% FCS.
Treatments
Cells were stimulated at a concentration of 5 Â 10 5 cells/ml. NKL cells were starved of IL-2 overnight, and stimulated with IL-2 (50 U/ml) for 15 min for immunoblotting and EMSA, 30 min for ChIP, and 2 or 24 h for harvesting mRNA. For BCL6 protein expression, NKL cells were starved of IL-2 for 3 days and stimulated with IL-2 for 1 or 2 days. BCL1-5B1b cells were stimulated with IL-2 (50 U/ml) for 15 min for immunoblots, 30 min for ChIP and 2 h for mRNA expression. 32D cells were starved of IL-3 overnight, and untreated or pretreated with dimethylsulfoxide, 20 mM LY294002 (Cell Signaling, Beverly, MA, USA) or 20 mM UO126 (Cell Signaling) for 1 h, and then stimulated with IL-3 (10 ng/ml) for 15 min for immunoblotting and 2 h for mRNA expression. K562 cells were untreated or treated with 1 mM STI-571 (Novartis, Cambridge, MA, USA) for 30 min for immunoprecipitations or 2 and 24 h for mRNA expression. Ba/f3-tet-1*6 cells were starved of IL-3 and stimulated with 1 mg/ml dox or starved for 16 h for mRNA expression.
Antibodies and immunoblotting
Immunoblots and immunoprecipitations were performed as described (Battle and Frank, 2003) . Antibodies used include phospho-specific STAT5 (9351), phospho-p44/42 MAPK (9101), p44/42 MAPK (9102), phospho-Akt (9271) and Akt (9272) from Cell Signaling; STAT5b (71-2500; Zymed, South San Francisco, CA, USA); and total STAT5 (sc-835), STAT5a (sc-1081), STAT1 (sc-346), STAT3 (sc-482) and BCL6 (sc-858) from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
mRNA expression RNA was harvested using an RNeasy Mini Kit from Qiagen (Valencia, CA, USA). cDNA was generated using the SuperScript First Stand Synthesis kit (Invitrogen, Carlsbad, CA, USA) or the TaqMan Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). Quantitative polymerase chain reaction (qPCR) was performed in triplicate using SYBR green master mix (Stratagene, La Jolla, CA, USA or Applied Biosystems) and the indicated primers (Table 1 ) on a 7500 realtime PCR system (Applied Biosystems). Data are expressed as mean fold change 7s.e.m. of three replicates.
mRNA stability For determination of mRNA half-life, NKL cells starved of IL-2 were pretreated with 5 mg/ml actinomycin D (Sigma) for 1 h, and then were untreated or stimulated with IL-2. RNA 
